hh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors
Southern Medical University, Guangzhou, China.
Southern Medical University, Guangzhou, China.
Southern Medical University, Guangzhou, China.ORCID iD: 0000-0001-7790-8197
Southern Medical University, Guangzhou, China.
2021 (English)In: Expert Opinion on Pharmacotherapy, ISSN 1465-6566, E-ISSN 1744-7666, Vol. 22, no 6, p. 715-728Article in journal (Refereed) Published
Abstract [en]

Introduction: Seasonal influenza vaccination, together with FDA-approved neuraminidase (NA) and polymerase acidic (PA) inhibitors, is the most effective way for prophylaxis and treatment of influenza infections. However, the low efficacy of prevailing vaccines to newly emerging influenza strains and increasing resistance to available drugs drives intense research to explore more effective inhibitors. Hemagglutinin (HA), one of the major surface proteins of influenza strains, represents an attractive therapeutic target to develop such new inhibitors. Areas covered: This review summarizes the current progress of HA-based influenza virus inhibitors and their mechanisms of action, which may facilitate further research in developing novel antiviral inhibitors for controlling influenza infections. Expert opinion: HA-mediated entry of influenza virus is an essential step for successful infection of the host, which makes HA a promising target for the development of antiviral drugs. Recent progress in delineating the crystal structures of HA, especially HA-inhibitors complexes, has revealed a number of key residues and conserved binding pockets within HA. This has opened up important insights for developing HA-based antiviral inhibitors that have a high resistance barrier and broad-spectrum activities.

Place, publisher, year, edition, pages
Abingdon: Taylor & Francis, 2021. Vol. 22, no 6, p. 715-728
Keywords [en]
Drug resistance, conserved binding pockets, hemagglutinin, influenza virus, inhibitors
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:hh:diva-48315DOI: 10.1080/14656566.2020.1856814ISI: 000603757800001PubMedID: 33327812Scopus ID: 2-s2.0-85098524246OAI: oai:DiVA.org:hh-48315DiVA, id: diva2:1702418
Note

Funding text: This work was funded by the National Natural Science Foundation of China [81728007], the Major scientific and technological projects of Guangdong Province [2019B020202002], the Chinese Academy of Traditional Chinese Medicine [ZZ13-035-02], and the Evidence-based capacity building project of Traditional Chinese Medicine [2019XZZX-LG04] awarded to S. Liu.

Available from: 2022-10-10 Created: 2022-10-10 Last updated: 2022-10-12Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Nandakumar, Kutty Selva

Search in DiVA

By author/editor
Nandakumar, Kutty Selva
In the same journal
Expert Opinion on Pharmacotherapy
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 6 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf